

CURRENT REPORT 34/2021

November 9, 2021

Ryvu Therapeutics to highlight HPK1 and STING Programs at the upcoming SITC Conference

The Management Board of Ryvu Therapeutics S.A. ("Company") hereby announces that the Company will present two research posters on its HPK1 and STING programs at the upcoming Society for Immunotherapy of Cancer 36th Annual Meeting & Pre-Conference Programs (SITC 2021) taking place on November 10 – 14, 2021, in Washington, DC.

The first poster concerns novel, orally administered HPK1 inhibitors which hold promising potential as a treatment in a variety of solid tumor indications. HPK1 inhibitors developed by the Company exhibit nanomolar activity in an immunosuppressive environment. These small molecules have shown favorable PK profiles allowing for in vivo target engagement after oral administration.

Poster presentation:

Novel, orally administered HPK1 inhibitors demonstrate anti-tumor efficacy and enhanced immune response (Abstract ID: 752), Maciej Kujawa et al.

On-site presentation session: November 13, 2021, 7:00 AM – 8:30 PM, Poster Hall E

The second poster will highlight a novel small-molecule STING agonist, RVU-27065. Selective STING pathway activation with RVU-27065 allows for repolarization of immunosuppressive tumor-associated macrophages into a pro-inflammatory phenotype without a negative impact on T-cell functioning. With favorable drug-like properties and good safety profile, RVU-27065 is a promising candidate for standalone treatment as well as targeted delivery as a payload for antibodies.

Poster presentation:

Characterization of RVU-27065 a novel small-molecule STING agonist suitable for systemic administration (Abstract ID: 764), Maciej Rogacki et al.

On-site presentation session: November 13, 2021, 7:00 AM – 8:30 PM, Poster Hall E

Both posters will be available online as of November 12, 7 AM ET at SITC's website: <https://sitc.sitcancer.org/2021/abstracts/titles/>

Legal basis: art. 17 ust. 1 MAR

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board